Eastern Equine Encephalitis (Infectious Disease) - Drugs in Development, 2021

December 2021 | 44 pages | ID: ED25F5AA4C4BEN
Global Markets Direct

Abstracts

Eastern Equine Encephalitis (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eastern Equine Encephalitis – Drugs In Development, 2021, provides an overview of the Eastern Equine Encephalitis (Infectious Disease) pipeline landscape.

Eastern equine encephalitis is a disease caused by a zoonotic mosquito vectored Togavirus that is present in North, Central, and South America, and the Caribbean. Eastern equine encephalitis (EEE) is an extremely rare and often fatal infection that causes encephalitis or inflammation of the brain. It is spread by the bite of a mosquito infected with EEE virus (EEEV). Severe cases of EEE infection begin with the sudden onset of headache, high fever, chills, and vomiting that may progress into disorientation, seizures, encephalitis (inflammation of the brain), and coma.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eastern Equine Encephalitis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Eastern Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eastern Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Eastern Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 3 molecules, respectively.

Eastern Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Eastern Equine Encephalitis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Eastern Equine Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Eastern Equine Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Eastern Equine Encephalitis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Eastern Equine Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Eastern Equine Encephalitis - Overview
Eastern Equine Encephalitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Eastern Equine Encephalitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Eastern Equine Encephalitis - Companies Involved in Therapeutics Development
Eastern Equine Encephalitis - Drug Profiles
Eastern Equine Encephalitis - Dormant Projects
Eastern Equine Encephalitis - Product Development Milestones
Featured News & Press Releases
Apr 18, 2019: UofL researcher developing drug to treat emerging encephalitis viruses
Jan 24, 2019: Bavarian Nordic advances development of equine encephalitis virus vaccine
Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Eastern Equine Encephalitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Eastern Equine Encephalitis - Pipeline by AlphaVax Inc, 2021
Eastern Equine Encephalitis - Pipeline by Auro Vaccines LLC, 2021
Eastern Equine Encephalitis - Pipeline by Bavarian Nordic A/S, 2021
Eastern Equine Encephalitis - Pipeline by Merck & Co Inc, 2021
Eastern Equine Encephalitis - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Eastern Equine Encephalitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021